Investors Investors

Stock Quote

NASDAQ: PGNX
$6.28
- 0.16
4:00 PM ET on August 31

Investor Relations

Progenics Investor relations Team works to provide, shareholders, analysts and potential investors with timely, relevant and reliable information.

We strive to make our press releases, scientific papers, and abstracts timely and accurate when issued. Subsequent events may affect their continued accuracy beyond the date of issuance and posting on the website. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties.

Presentations

Corporate Presentation

Offer to Purchase the shares of EXINI Diagnostics AB October 13, 2015

Progenics - Förlängd acceptperiod i Progenics erbjudande om förvärv av aktierna i EXINI avslutad

Progenics - Extended acceptance period in Progenics offer to acquire the shares in EXINI has ended

Progenics declares the offer for EXINI unconditional (Swedish language version)

Progenics declares the offer for EXINI unconditional (English language version)

Acceptance Form for Exini Shareholders

Progenics - Offer document (Swedish)

Progenics - Offer document (English)

Progenics - Offer announcement for release (Swedish)

Progenics - Offer announcement for release (English).pdf

EXINI - Press Release (Swedish)

EXINI - Press Release (English)

View all »   RSSRecent Releases

Aug 4, 2016
Progenics Pharmaceuticals Announces Second Quarter 2016 Financial and Business Results

Jul 26, 2016
Progenics Receives $50 Million Milestone Payment Following FDA Approval of RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain